Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States.
Where this comes from
- Record sourced from PubMed, PMID 26978062.
- Also identified by DOI 10.1371/journal.pone.0151362 and PMC identifier 4792468.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and 2013. Associated information on underlying diseases, demographics, institutional use, mortality, and physician type was collected. Exposure to bortezomib was identified in 314 patients. Hematologist/Oncologists prescribed half of the bortezomib used. Use increased during the study period. Inpatient volume was positively correlated with bortezomib utilization. Bortezomib use in pediatrics is increasing for a variety of diseases. Variation in use exists across institutions. Further studies are needed to characterize bortezomib's efficacy in pediatric diseases.
Medical subject headings
- Bortezomib
- Drug Prescriptions
- Hospitals, Pediatric
- Practice Patterns, Physicians'